Sareyeldin Rasha M, Gupta Ishita, Al-Hashimi Israa, Al-Thawadi Hamda A, Al Farsi Halema F, Vranic Semir, Al Moustafa Ala-Eddin
College of Medicine, Qatar University, Doha 2713, Qatar.
Biomedical Research Centre, Qatar University, Doha 2713, Qatar.
Cancers (Basel). 2019 May 10;11(5):646. doi: 10.3390/cancers11050646.
Breast cancer is the second most common cause of cancer-related deaths among women worldwide. It is a heterogeneous disease with four major molecular subtypes. One of the subtypes, human epidermal growth factor receptor 2 (HER2)-enriched (HER2-positive) is characterized by the absence of estrogen and progesterone receptors and overexpression of HER2 receptor, and accounts for 15-20% of all breast cancers. Despite the anti-HER2 and cytotoxic chemotherapy, HER2 subtype is an aggressive disease with significant mortality. Recent advances in molecular biology techniques, including gene expression profiling, proteomics, and microRNA analysis, have been extensively used to explore the underlying mechanisms behind human breast carcinogenesis and metastasis including HER2-positive breast cancer, paving the way for developing new targeted therapies. This review focuses on recent advances on gene expression and miRNA status in HER2-positive breast cancer.
乳腺癌是全球女性癌症相关死亡的第二大常见原因。它是一种具有四种主要分子亚型的异质性疾病。其中一种亚型,即人表皮生长因子受体2(HER2)富集型(HER2阳性),其特征是缺乏雌激素和孕激素受体且HER2受体过表达,占所有乳腺癌的15%至20%。尽管有抗HER2和细胞毒性化疗,但HER2亚型是一种侵袭性疾病,死亡率很高。包括基因表达谱分析、蛋白质组学和微小RNA分析在内的分子生物学技术的最新进展已被广泛用于探索包括HER2阳性乳腺癌在内的人类乳腺癌发生和转移的潜在机制,为开发新的靶向治疗方法铺平了道路。本综述重点关注HER2阳性乳腺癌中基因表达和微小RNA状态的最新进展。